Last reviewed · How we verify
CSII(insulin Lispro)
CSII(insulin Lispro) is a Rapid-acting insulin analog Small molecule drug developed by The First Affiliated Hospital of Xiamen University. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when insulin therapy is required).
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Insulin Lispro is a protein-based insulin receptor agonist used to treat various forms of diabetes, including Type 1 and Type 2 Diabetes Mellitus. It is classified as an agonist and is used in insulin pump therapy.
At a glance
| Generic name | CSII(insulin Lispro) |
|---|---|
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro is a recombinant human insulin analog with a rapid onset of action (10-15 minutes) and shorter duration compared to regular human insulin. When administered via continuous subcutaneous insulin infusion (CSII), it mimics the body's natural postprandial insulin secretion by binding to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when insulin therapy is required)
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
- Weight gain
Key clinical trials
- A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps (PHASE1)
- A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy (PHASE3)
- A Study of LY900014 in a Medtronic Pump (PHASE2)
- A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus (PHASE1)
- A Study of LY900014 in Participants With Type 1 Diabetes Mellitus (PHASE1)
- A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes (PHASE3)
- A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes (NA)
- A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSII(insulin Lispro) CI brief — competitive landscape report
- CSII(insulin Lispro) updates RSS · CI watch RSS
- The First Affiliated Hospital of Xiamen University portfolio CI
Frequently asked questions about CSII(insulin Lispro)
What is CSII(insulin Lispro)?
How does CSII(insulin Lispro) work?
What is CSII(insulin Lispro) used for?
Who makes CSII(insulin Lispro)?
What drug class is CSII(insulin Lispro) in?
What development phase is CSII(insulin Lispro) in?
What are the side effects of CSII(insulin Lispro)?
What does CSII(insulin Lispro) target?
Related
- Drug class: All Rapid-acting insulin analog drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: The First Affiliated Hospital of Xiamen University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus (when insulin therapy is required)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing